Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

BCMA-CART therapy in 29 cases of relapsed or refractory multiple myeloma:a retrospective study

View Full Paper
Ask AI
Bookmark
Share

Authors

MYMin YangHMHaitao MengJJJie Jin

Discussion

Loading...

Member takes

Overview

Retrospective study highlights positive response rates after BCMA-directed CAR-T therapy in relapsed multiple myeloma, indicating potential for long-term survival.

Key Points

  • After BCMA CAR-T therapy, 28 of 29 relapsed multiple myeloma patients responded, 15 achieving stringent complete response.
  • Median progression-free survival was 29.2 months, while overall survival reached 36.7 months, suggesting durable outcomes.
  • Assessment utilized International Myeloma Working Group criteria and fluorescence in situ hybridization for cytogenetic abnormalities.
  • Findings imply potential for BCMA-directed CAR-T therapy to improve long-term outcomes in high-risk multiple myeloma patients.

Cite This Study

Yang et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc12https://doi.org/10.1182/blood-2025-7610
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long-term follow-up of patients with relapsed/refractory multiple myeloma after BCMA CAR-T-cell therapy2025 · 3 citations
  2. 2CAC-MM-001: Anti-BCMA CAR-T therapy followed by autologous stem cell transplantation and second CAR-T (CART-ASCT-CART2) in newly diagnosed multiple myeloma patients with P53 gene abnormalities.2025 · 2 citations
  3. 3Anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma with extramedullary disease: Comparative outcomes and evolving strategies2025
  4. 4BCMA CAR T-cell therapy in newly diagnosed primary plasma cell leukemia ineligible for transplantation: An open label, single-arm, phase 2 study (CAREMM-002)2025 · 1 citations
  5. 5High risk MDS in the wke of anti-BCMA CART therapy in refractory multiple myeloma.2025